Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy

[1]  P. Neven,et al.  The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters , 2016, Oncotarget.

[2]  T. Lüscher,et al.  MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. , 2016, European heart journal.

[3]  P. Neven,et al.  Biological ageing and frailty markers in breast cancer patients , 2015, Aging.

[4]  Jin Gao,et al.  Prognostic value of miR-106b expression in breast cancer patients. , 2015, The Journal of surgical research.

[5]  H. Wildiers,et al.  Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Zhi-xin Wang,et al.  miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway , 2015, Oncotarget.

[7]  H. Wildiers,et al.  Circulating MicroRNAs as Easy-to-Measure Aging Biomarkers in Older Breast Cancer Patients: Correlation with Chronological Age but Not with Fitness/Frailty Status , 2014, PloS one.

[8]  Hui Li,et al.  Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer , 2014, Medical Oncology.

[9]  G. Meister,et al.  A Circulating MicroRNA Profile Is Associated with Late-Stage Neovascular Age-Related Macular Degeneration , 2014, PloS one.

[10]  H. Wildiers,et al.  International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Bours,et al.  Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression , 2014 .

[12]  Yasmin Anum Mohd Yusof,et al.  Expression of Senescence-Associated microRNAs and Target Genes in Cellular Aging and Modulation by Tocotrienol-Rich Fraction , 2014, Oxidative medicine and cellular longevity.

[13]  H. Wildiers,et al.  Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? , 2014, Journal of geriatric oncology.

[14]  M. Kerin,et al.  Impact of Tumour Epithelial Subtype on Circulating microRNAs in Breast Cancer Patients , 2014, PloS one.

[15]  Graham Ball,et al.  Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer , 2014, PloS one.

[16]  N. Robert,et al.  Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. , 2013, The Lancet. Oncology.

[17]  A. Mansfield,et al.  Normal ageing is associated with an increase in Th2 cells, MCP‐1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF‐AA between sexes , 2012, Clinical and experimental immunology.

[18]  M. Satoh,et al.  MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. , 2012, Clinical science.

[19]  S. Schreiber,et al.  Genome‐wide miRNA signatures of human longevity , 2012, Aging cell.

[20]  K. Kelnar,et al.  Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. , 2012, Cancer research.

[21]  A. Zekri,et al.  MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[22]  G. Tsujimoto,et al.  Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells , 2012, PloS one.

[23]  L. Silengo,et al.  The aging effect of chemotherapy on cultured human mesenchymal stem cells. , 2011, Experimental hematology.

[24]  H. Wildiers,et al.  p16INK4a: A central player in cellular senescence and a promising aging biomarker in elderly cancer patients , 2011 .

[25]  D. Beach,et al.  Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21Waf1/Cip1 , 2010, Oncogene.

[26]  Yi Tie,et al.  miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. , 2009, Cancer letters.

[27]  Sharon J. Diskin,et al.  A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene , 2008, Molecular Cancer Research.

[28]  Izumi Horikawa,et al.  Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. , 2008, Cancer research.

[29]  L. Lim,et al.  MicroRNAs in the miR-106b Family Regulate p21/CDKN1A and Promote Cell Cycle Progression , 2008, Molecular and Cellular Biology.

[30]  H. Bartelink,et al.  Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. , 2007, The Lancet. Oncology.

[31]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[32]  K. Riabowol,et al.  Acceleration of Telomere Loss by Chemotherapy Is Greater in Older Patients with Locally Advanced Head and Neck Cancer , 2006, Clinical Cancer Research.

[33]  Alessandro Antonelli,et al.  Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. , 2006, Cytokine.

[34]  S. Leng,et al.  Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty , 2004, Aging clinical and experimental research.

[35]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[36]  Christoph Lehner,et al.  Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. , 2003, Clinical science.

[37]  S. Cho,et al.  Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy , 2003, Annals of Hematology.

[38]  R. Cawthon,et al.  Association between telomere length in blood and mortality in people aged 60 years or older , 2003, The Lancet.

[39]  S. Franco,et al.  Telomere dynamics in childhood leukemia and solid tumors: a follow-up study , 2003, Leukemia.

[40]  G. Wisman,et al.  Human Telomere Length in Breast Cancer Patients before and after Chemotherapy with or without Stem Cell Transplantation , 2000 .

[41]  C. Franceschi,et al.  Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians , 2001, Mechanisms of Ageing and Development.

[42]  I. Blasko,et al.  An imbalance between pro- and anti-inflammatory cytokines, a characteristic feature of old age. , 2000, Cytokine.

[43]  M. Extermann,et al.  Management of cancer in the older person: a practical approach. , 2000, The oncologist.

[44]  M. Extermann,et al.  Management of the frail person with advanced cancer. , 2000, Critical reviews in oncology/hematology.

[45]  Luigi Ferrucci,et al.  Serum IL‐6 Level and the Development of Disability in Older Persons , 1999, Journal of the American Geriatrics Society.

[46]  H J Cohen,et al.  The association of plasma IL-6 levels with functional disability in community-dwelling elderly. , 1997, The journals of gerontology. Series A, Biological sciences and medical sciences.

[47]  T. Blondal,et al.  Assessing sample and miRNA profile quality in serum and plasma or other biofluids. , 2013, Methods.

[48]  Jianyi Li,et al.  Effects of differential distribution of microvessel density, possibly regulated by miR-374a, on breast cancer prognosis. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[49]  J. Armitage,et al.  Myeloid growth factors. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[50]  J. Armitage,et al.  Myeloid growth factors. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[51]  R. Maccormick.  Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? , 2006, Medical hypotheses.